XML 48 R37.htm IDEA: XBRL DOCUMENT
v3.25.3

Research and Development and In-Licensing Arrangement - Narrative (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Sep. 28, 2025 | Jul. 31, 2025 | Mar. 30, 2025 | Sep. 28, 2025 | Sep. 29, 2024 | Sep. 28, 2025 | Sep. 29, 2024
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  | $ 1,390 | $ 13 | $ 1,401 | $ 20
Abingworth [Member] |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Research and development arrangement, maximum funding amount | $ 200 |  |  |  |  |  |
Abingworth [Member] | Clinical Trial Agreement Terms [Member] |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Maximum potential cash payments | $ 120 |  |  | $ 120 |  | $ 120 |
Abingworth [Member] | Approval Based Payment Period [Member] |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Payment period (in years) | 18 years |  |  | 18 years |  | 18 years |
Abingworth [Member] | Net Sales and Royalty Agreement Terms [Member] |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Maximum potential cash payments | $ 280 |  |  | $ 280 |  | $ 280 |
Payment period (in years) | 1 year |  |  | 1 year |  | 1 year |
Blackstone [Member] |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Research and development arrangement, maximum funding amount |  |  | $ 326 |  |  |  |
Blackstone [Member] | Clinical Trial Agreement Terms [Member] |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Maximum potential cash payments |  |  | 277 |  |  |  |
Blackstone [Member] | Approval Based Payment Period [Member] | Minimum [Member] |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Payment period (in years) | 1 year |  |  | 1 year |  | 1 year |
Blackstone [Member] | Approval Based Payment Period [Member] | Maximum [Member] |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Payment period (in years) | 3 years |  |  | 3 years |  | 3 years |
Blackstone [Member] | Net Sales and Royalty Agreement Terms [Member] |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Maximum potential cash payments |  |  | $ 897 |  |  |  |
Blackstone [Member] | Net Sales and Royalty Agreement Terms [Member] | Minimum [Member] |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Payment period (in years) | 5 years |  |  | 5 years |  | 5 years |
Blackstone [Member] | Net Sales and Royalty Agreement Terms [Member] | Maximum [Member] |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Payment period (in years) | 7 years |  |  | 7 years |  | 7 years |
3SBio [Member] | In-Licensing Agreement [Member] |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Maximum potential cash payments |  | $ 4,800 |  |  |  |  |
Upfront payment |  | 1,250 |  |  |  |  |
Equity investment |  | 100 |  |  |  |  |
3SBio [Member] | In-Licensing Agreement Option [Member] |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Upfront payment |  | 100 |  |  |  |  |
Option exercise fee |  | 50 |  |  |  |  |
Acquired in-process research and development expenses |  | $ 1,350 |  | $ 1,350 |  | $ 1,350 |

X
- Definition Research And Development Arrangement, Contingent Payments, Maximum Exposure1 + References No definition available. + Details
Name: | pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Research And Development Arrangement, Contingent Payments, Option Exercise Fee + References No definition available. + Details
Name: | pfe_ResearchAndDevelopmentArrangementContingentPaymentsOptionExerciseFee
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research And Development Arrangement, Contingent Payments, Payment Period + References No definition available. + Details
Name: | pfe_ResearchAndDevelopmentArrangementContingentPaymentsPaymentPeriod
Namespace Prefix: | pfe_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Research And Development Arrangement, Maximum Funding Amount + References No definition available. + Details
Name: | pfe_ResearchAndDevelopmentArrangementMaximumFundingAmount
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research And Development Arrangement, Upfront Payment + References No definition available. + Details
Name: | pfe_ResearchAndDevelopmentArrangementUpfrontPayment
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details
Name: | us-gaap_PaymentsToAcquireEquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=pfe_AbingworthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pfe_ClinicalTrialAgreementTermsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pfe_ApprovalBasedPaymentPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pfe_NetSalesAndRoyaltyAgreementTermsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pfe_BlackstoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pfe_A3SBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_InLicensingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_InLicensingAgreementOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |